AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27397441
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 mcg/kg loading dose over 15 min, followed by 0.5 mcg/kg/h maintenance infusion)
Trial: 17073850
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with a plasmatic target concentration of 4 mg/l (group P; n= 26)
Trial: 16338276
Drug: Saquinavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (600 mg) with water (control)
Trial: 16338276
Drug: Saquinavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (600 mg) with Seville orange juice
Trial: 7720343
Drug: Random urine
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random urine sample with threshold albumin-creatinine ratio of > or = 3.0 mg/mmol
Trial: 7720343
Drug: Overnight urine
RxNorm normalized name: URINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight urine collection with threshold values of 2.5 mg/mmol for men and 4.5 mg/mmol for women
Trial: 2119417
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg b.i.d. for 6 weeks, then 20 mg b.i.d. for 6 weeks)
Trial: 29373395
Drug: Real rDTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rDTMS treatment
Trial: 29373395
Drug: Sham rDTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rDTMS treatment
Trial: 28318388
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention with individualized nutrition plan (1.0‐1.5 g/kg) and dietary advice
Trial: 18249333
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standardized institutional practice without warmed intravenous fluids)
Trial: 1625092
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (hGH) alone
Trial: 2681348
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with hGH and oxandrolone
Trial: 27655325
Drug: 4 mL/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/Kg of crystalloid
Trial: 26588599
Drug: Flapless surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flapless surgical protocol (n = 20 patients; 32 implants)
Trial: 26588599
Drug: Flapped surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flapped surgical protocol (n = 21 patients; 40 implants)
Trial: 24982464
Drug: VAC (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (vincristine, dactinomycin, and cyclophosphamide) with 1.5 g/m² of cyclophosphamide
Trial: 24982464
Drug: VAI (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAI (vincristine, dactinomycin, and ifosfamide) with 6 g/m² of ifosfamide
Trial: 19244263
Drug: Levobupivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine infusion for femoral nerve
Trial: 19244263
Drug: Levobupivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine infusion for sciatic nerve
Trial: 9788829
Drug: Echocardiography-guided ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echocardiography-guided ethanol septal reduction (2 to 5 mL of absolute ethanol injected into the septal artery)
Trial: 15130899
Drug: Intramuscular gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gold
Trial: 892953
Drug: Drug +
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug + alcohol placebo
Trial: 24021094
Drug: Progressive Goal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Goal Attainment Program (PGAP) - 10 weekly individual sessions of structured active rehabilitation in addition to usual care.
Trial: 22409094
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (receiving cognitive behavioral therapy and pharmacotherapy)
Trial: 19603054
Drug: 5‐methyltetrahydrofolate (5‐MTHF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methyltetrahydrofolate (5‐MTHF) 15 mg/day for 3 weeks
Trial: 9740919
Drug: Comprehensive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive management approach including preoperative evaluation, meticulous exenterative surgery, supervised immunotherapy, medical management with corticosteroids, patient self-cleansing, and close clinical follow-up.
Trial: 27127315
Drug: Alfuzosin SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin SR 10 mg
Trial: 23203138
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride XR 60 mg once daily for 10 days in healthy volunteers
Trial: 23203138
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 60 mg XR once daily for either 2 weeks or 12 weeks in patients with overactive bladder
Trial: 23203138
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride XR 60 mg
Trial: 17710365
Drug: GLU +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU + FG (1.8 g x kg BW(‐1) + 1.99 +/‐ 0.20 mg x kg(‐1) 4‐hydroxyisoleucine)
Trial: 1745512
Drug: Pilocarpine (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (2% liquid ophthalmic drop preparation, four drops three times per day for 6 weeks)
Trial: 1745512
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically appearing solution, same dosing schedule and duration)
Trial: 6751182
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (nafcillin for 6 weeks plus gentamicin for 2 weeks) in parenteral drug addicts
Trial: 6751182
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (nafcillin for 6 weeks plus gentamicin for 2 weeks) in nonaddicts
Trial: 6751182
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy (nafcillin for 6 weeks) in both groups
Trial: 23545428
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose morphine/oxycodone (3 mg/2 mg)
Trial: 23545428
Drug: Flexible dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dose morphine/oxycodone
Trial: 19137769
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment
Trial: 12824978
Drug: Intravenous ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ritodrine (111 microg/min for 20 minutes)
Trial: 9832096
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (0.4 mg)
Trial: 12824978
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium chloride 0.9% (placebo)
Trial: 10638892
Drug: Bupivacaine 4
RxNorm normalized name: BUPIVACAINE 400MG/MELOXICAM 12MG/VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 4 mg plus fentanyl 20 microg (Group A)
Trial: 10638892
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mg (Group B)
Trial: 3090492
Drug: Levonorgestrel‐releasing Norplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel‐releasing Norplant implants
Trial: 20685721
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency treatment
Trial: 21679043
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac 37.5 mg
Trial: 8665883
Drug: ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg
Trial: 21056807
Drug: oral acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral acetylsalicylic acid (ASA) 325 mg
Trial: 21056807
Drug: oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral diclofenac 50 mg
Trial: 17693428
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment (appliance removal)
Trial: 12410188
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home PCA monitoring
Trial: 6826111
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyloestradiol plus 2.5 mg norethisterone
Trial: 17555114
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant erythropoietic agents (specific dosage schemes not provided)
Trial: 17555114
Drug: Darbopoietin alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbopoietin alpha (specific dosage schemes not provided)
Trial: 11966551
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (NO-generating gel)
Trial: 6342359
Drug: Extensive radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extensive radiation therapy (RT) followed by chemotherapy (CT)
Trial: 31797710
Drug: Carnitine infusion
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carnitine infusion over 10 min 2 hours prior to radiocontrast administration and 24 hours post CT
Trial: 31797710
Drug: Tadalafil administration
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil administration 2 hours prior to radiocontrast administration and the subsequent day
Trial: 17976261
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) preparation of racemic ibuprofen
Trial: 16390770
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day 17beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Trial: 16390770
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day 17beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Trial: 12581544
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg/d to 400 mg/d)
Trial: 7533824
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (100 mg/m2/week or 80 mg/m2/week for prior radiation therapy patients)
Trial: 7740337
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine
Trial: 824875
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term treatment with Partusisten only
Trial: 31527700
Drug: Hypnosis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis plus treatment-as-usual (EG, n=8)
Trial: 31527700
Drug: Treatment-as-usual only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual only (CG, n=10)
Trial: 17096032
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (exact dosage and duration not specified)
Trial: 9285885
Drug: Zinc absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc absorption from a standard breakfast labelled with 3 mg 67Zn.
Trial: 9285885
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.5 mg 70Zn (as citrate).
Trial: 9285885
Drug: Urinary zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary zinc excretion measurement.
Trial: 8362773
Drug: Fosinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10 to 40 mg)
Trial: 8362773
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 to 20 mg)
Trial: 9568783
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements
Trial: 24114665
Drug: Specific anti-osteoporotic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific anti-osteoporotic drugs
Trial: 24114665
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D use among specific osteoporosis drug users
Trial: 20934601
Drug: Passion fruit
RxNorm normalized name: passion fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passion fruit peel extract (PFP), 150 mg daily for 2 months
Trial: 12803510
Drug: lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 10 mg/day
Trial: 12803510
Drug: lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 10 mg/day and pentoxifylline 600 mg/day for nine months
Trial: 7056105
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil therapy in chronic AF with rapid rate at rest
Trial: 7056105
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil therapy in chronic AF with accelerated rate during exercise
Trial: 7056105
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil therapy in paroxysmal AF
Trial: 25142999
Drug: Lopinavir-ritonavir (LPV-r)
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (LPV-r) 400-100 mg twice/day for 29.5 days followed by P. ginseng 500 mg twice/day for 2 weeks
Trial: 25142999
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng 500 mg twice/day for 2 weeks
Trial: 21070230
Drug: telcagepant 280/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 280/300 mg
Trial: 18614724
Drug: Sugared cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugared cocoa (22 g cocoa powder)
Trial: 2190933
Drug: Cefuroxime (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (one dose)
Trial: 489772
Drug: Once-daily sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily sotalol administration (80 to 320 mg)
Trial: 489772
Drug: Twice-daily sotalol
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily sotalol administration (80 to 320 mg)
Trial: 23856779
Drug: Deleobuvir 800
RxNorm normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deleobuvir 800 mg q8h for 5 days
Trial: 23856779
Drug: Deleobuvir 1200
RxNorm normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deleobuvir 1200 mg q8h for 5 days
Trial: 21881539
Drug: 10-mg ramipril
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg ramipril
Trial: 17372095
Drug: Duct tape
RxNorm normalized name: Sus scrofa bile duct preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duct tape occlusion therapy (moleskin with transparent duct tape)
Trial: 14980943
Drug: Prophylactic infusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusion of IV phenylephrine at 100 microg/min for 3 min, then 100 microg/min as needed
Trial: 8175974
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose human synthetic BNP infusion (4 pmol/kg.min for 1 h)
Trial: 3066519
Drug: Rifaximin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (three 200 mg tablets/die for 7 days)
Trial: 27544607
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) implantation
Trial: 12492745
Drug: Pantoprazole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 10 mg
Trial: 10632407
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FSH treatment)
Trial: 9010698
Drug: Entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (200 mg) and Imipramine (75 mg) in combination
Trial: 28490581
Drug: Four-valent HPV
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-valent HPV vaccine
Trial: 22713768
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated in 97 children
Trial: 25448437
Drug: Gp 2
RxNorm normalized name: Pulmari GP 20mg-100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gp 2 - oral health education talk and parental toothbrushing training, reinforced every 6 months
Trial: 20380654
Drug: Initial subcutaneous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial subcutaneous bolus of 1.4 U
Trial: 20380654
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion without initial bolus
Trial: 17666472
Drug: Cinacalcet hydrochloride
RxNorm normalized name: Cinacalcet Hydrochloride
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet hydrochloride (30 mg twice daily to 90 mg four times daily) for 16 weeks
Trial: 8369579
Drug: Cyclosporin 5
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 5 mg/kg/day
Trial: 8369579
Drug: Etretinate 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate 0.75 reduced to 0.5 mg/kg/day
Trial: 8369579
Drug: Cyclosporin maintenance
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin maintenance therapy 2.5‐5 mg/kg/day
Trial: 29482397
Drug: Dual-pulsed 532-nm/1064-nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-pulsed 532-nm/1064-nm QS laser treatment
Trial: 29482397
Drug: Single-pulsed 1064-nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pulsed 1064-nm Nd:YAG laser treatment
Trial: 24304551
Drug: rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI)
Trial: 24304551
Drug: PCI without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCI without statin therapy (control group)
Trial: 22394023
Drug: Dowels stored
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dowels stored for 30 days in aqueous solution at 37°C
Trial: 19706212
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplements (IFA; 60 mg Fe, 500 microg folic acid)
Trial: 19706212
Drug: Leaf concentrate
RxNorm normalized name: Belladonna Leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaf concentrate (LC; 5 mg Fe, 13 microg folic acid)
Trial: 23724913
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg orally twice daily)
Trial: 26483333
Drug: Chemotherapy (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (docetaxel 75 mg/m2 every three weeks)
Trial: 23672993
Drug: AHR-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHR-guided treatment strategy
Trial: 21719901
Drug: CHO solution
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO solution (1.2 g CHO/kg body mass)
Trial: 7490363
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of UVA/UVB sunscreen for 24 months
Trial: 9684126
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg once daily)
Trial: 11802750
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily)